Clene Inc.
General ticker "CLNN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $63.3M (TTM average)
Clene Inc. does not follow the US Stock Market performance with the rate: -7.1%.
Estimated limits based on current volatility of 4.8%: low 3.77$, high 4.15$
Factors to consider:
- Total employees count: 79 (+3.9%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Product development failure, Regulatory and compliance, Insufficient capital, Manufacturing scale up, Intellectual property risks
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.98$, 14.25$]
- 2026-12-31 to 2027-12-31 estimated range: [2.49$, 9.49$]
Financial Metrics affecting the CLNN estimates:
- Negative: with PPE of -2.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -97.03 <= 7.04
- Positive: -0.14 < Investing cash flow per share per price, % of -0.06
- Negative: 2.54 < Interest expense per share per price, % of 4.43
- Positive: Inventory ratio change, % of 0.34 <= 0.41
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CLNN quotes
Long-term CLNN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.65MM | $0.34MM | $0.20MM |
| Operating Expenses | $41.19MM | $33.44MM | $23.28MM |
| Operating Income | $-40.54MM | $-33.09MM | $-23.08MM |
| Non-Operating Income | $-8.96MM | $-6.31MM | $-3.09MM |
| Interest Expense | $4.56MM | $4.06MM | $2.68MM |
| R&D Expense | $26.66MM | $20.06MM | $14.01MM |
| Income(Loss) | $-49.50MM | $-39.40MM | $-26.17MM |
| Net Income(Loss)* | $-49.50MM | $-39.40MM | $-26.17MM |
| Stockholders Equity | $13.39MM | $-8.86MM | $-17.59MM |
| Inventory | $0.04MM | $0.07MM | $0.04MM |
| Assets | $52.34MM | $27.34MM | $18.13MM |
| Operating Cash Flow | $-30.17MM | $-21.33MM | $-18.55MM |
| Capital expenditure | $0.33MM | $0.01MM | $0.04MM |
| Investing Cash Flow | $-1.50MM | $6.32MM | $-0.04MM |
| Financing Cash Flow | $42.16MM | $-1.53MM | $11.52MM |
| Earnings Per Share** | $-9.43 | $-5.67 | $-2.65 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.